July 27, 2026  ·  Weekly Newsletter

Good morning, Reader.

Enhancer activity: The indirect chromatin modulation that reshapes gene expression leads this edition. It's the story that kept surfacing in the papers this week, and when something keeps coming back up it's usually because the implications are wider than the headline suggests. Read that one first.

There are 9 pieces in total, spanning several therapy areas. Some you'll want to read now. Some are worth flagging for a quieter moment. But at least one will shift how you're thinking about a clinical question you've been sitting with.

ESC 2026 is Aug 28 – 31, 2026 in Munich. We'll have summaries, key data, and anything that surfaces worth knowing. If there's a specific trial you're watching, hit reply. I read every one.

The honest question this week is how fast things are moving for your patients specifically. Some of what's in here is already in practice. Some is three years out. Knowing which is which is the job. I read every reply.

Until next week,
William Lopes
Editor, The Life Science Feed

Genomic Medicine

The precise control of gene expression dictates cellular function and differentiation, a process often initiated by enhancers. These regulatory elements, once activated, are known to directly influence their target genes. But the full scope of their influence, particularly on genes not immediately adjacent, has remained a subject of mechanistic inquiry, challenging the conventional understanding of transcriptional regulation. A deeper understanding of these indirect effects could reshape our…